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Biological molecules are increasingly becoming a part of the therapeutics portfolio that 
has been either recently approved for marketing or those that are in the pipeline of 
several biotech and pharmaceutical companies. This is largely based on their ability 
to be highly specific relative to small molecules. However, by virtue of being a large 
protein, and having a complex structure with structural variability arising from production 
using recombinant gene technology in cell lines, such therapeutics run the risk of being 
recognized as foreign by a host immune system. In the context of immune-mediated 
adverse effects that have been documented to biological drugs thus far, including 
infusion reactions, and the evolving therapeutic platforms in the pipeline that engineer 
different functional modules in a biotherapeutic, it is critical to understand the interplay of 
the adaptive and innate immune responses, the pathophysiology of immunogenicity to 
biological drugs in instances where there have been immune-mediated adverse clinical 
sequelae and address technical approaches for their laboratory evaluation. The current 
paradigm in immunogenicity evaluation has a tiered approach to the detection and char-
acterization of anti-drug antibodies (ADAs) elicited in vivo to a biotherapeutic; alongside 
with the structural, biophysical, and molecular information of the therapeutic, these 
analytical assessments form the core of the immunogenicity risk assessment. However, 
many of the immune-mediated adverse effects attributed to ADAs require the formation 
of a drug/ADA immune complex (IC) intermediate that can have a variety of downstream 
effects. This review will focus on the activation of potential immunopathological pathways 
arising as a consequence of circulating as well as cell surface bound drug bearing ICs, 
risk factors that are intrinsic either to the therapeutic molecule or to the host that might 
predispose to IC-mediated effects, and review the recent literature on prevalence and 
intensity of established examples of type II and III hypersensitivity reactions that follow 
the administration of a biotherapeutic. Additionally, we propose methods for the study 
of immune parameters specific to the biology of ICs that could be of use in conjunction 
with the detection of ADAs in circulation.
Keywords: immunogenicity, biotherapeutics, hypersensitivity, neutralizing antibodies, immune complexes, risk 
assessment, immunogenicity prediction, immunogenicity assay
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iNTRODUCTiON
Immunogenicity is antigenicity in an inflammatory milieu 
resulting in a successful humoral response. With evolving protein 
therapeutic platforms, newer multi-domain therapeutics and the 
escalating investment of resources and technology toward the 
development of efficacious biologic drugs with minimal adverse 
effects, the phenomenon of immunogenicity has gained added 
relevance (1–7). Anti-drug antibodies (ADAs) can be elicited 
in  vivo to a therapeutic and their detection has generally been 
equated as a measure of immunogenicity. The detection, report-
ing, and characterization of the ADA are done in a tiered manner 
after careful consideration of immunogenic risk factors. (8, 9). 
Most adverse effects consequential to ADA formation, such as 
pharmacological abrogation, impact on therapeutic exposure, 
or hypersensitivity reactions, are a consequence of formation 
of immune complexes (ICs) between the ADA and therapeutic 
protein. Their levels, kinetics of interaction, size, polyclonal 
diversity, distribution, and Fc-mediated physiological effects can 
be potentially translated to clinically observable adverse effects. 
This leads to the paradigm of immunogenicity where therapeutic 
exposure leads to ADA generation that in turn forms ICs that 
mediate adverse effects related to immunogenicity.
While the detection of such therapeutic specific IC from 
in vivo samples has remained analytically challenging, there are 
other biomarkers that mediate the interplay of the innate and 
adaptive immune responses and are potentially amenable to 
analysis. Such markers can reflect either the formation or the 
downstream effects of ICs. Molecular pathways underlying the 
immune response have been extensively studied to understand 
the pathophysiology of several autoimmune conditions (10) and 
it is most likely to be a question of degree and intensity of their 
involvement in an immune response to a therapeutic agent. The 
hope is to identify and describe some of these pathways whose 
analysis can be integrated pragmatically into the immunogenic-
ity risk management process and consistently applied across 
the biotechnology industry for a shared learning across diverse 
therapeutic platforms. Considerable effort and progress has been 
made in identifying and mitigating risk factors from a therapeutic 
entity perspective – such as molecular engineering, formulation, 
biophysical character, route of delivery, and sequences with a 
propensity for binding to various MHC alleles. However from an 
in vivo perspective, there are host-specific phenotypic markers, 
some of which are polymorphic, with the distribution of Class II 
alleles in different populations being perhaps the most dominant 
example of such a host-specific characteristic (Table  1). These 
attributes in a host might explain the variability in ADA levels 
and their downstream effects or influence the formation and 
behavior of ICs. This would thereby represent the other half of 
the immunogenicity equation that needs to be considered as part 
of the total risk assessment package.
Therapeutic molecules bound to cell surface protein targets 
may also attract circulating ADA leading to formation of ICs 
on cell membranes in tissues; adverse effects due to these are 
classified as type II reactions. ADA bound to drug in circulation 
gives rise to circulating ICs (CICs) and they can result in type 
III reactions. Regardless of their presence, ICs are relevant from 
two main points of analysis – their size and their propensity to 
activate complement. Both factors can drive formation of IC 
deposits and activation of inflammatory pathways. The size of the 
complex also affects Fc-mediated functions through interaction 
with a family of widely distributed activating Fc receptors (FcRs). 
FcR expression levels vary in individuals. In addition, there are 
naturally occurring polymorphisms in their type and distribution 
that influences Fc-mediated effects by the ICs.
This review will also summarize salient examples where ADA 
generation was related to clinically observed immune-related 
adverse effects and where characteristics of ICs could explain 
the molecular mechanisms underlying the clinical data. The 
case reports will focus on those where the clinical presentation 
represents an underlying type I or type II hypersensitivity.
BiOLOGiCAL eFFeCTS OF iMMUNe 
COMPLeXeS
Activation of Fc Receptors
Fcγ receptors (FcγR) are widely expressed by several cell types in 
the hematopoietic system and play a primary role in pathological 
effects of ICs. High-affinity FcγR1 binds monomeric IgG but low 
affinity FcγRII (CD32) and FcγRIII (CD16) preferentially bind 
complexed IgG. They are present in multiple isoforms and can be 
classified as activating (FcγRIIA, FcγRIIIA) or inhibiting (FcγRIIB, 
FcγRIIIB) depending on their cytoplasmic motifs (11, 12). ICs typi-
cally with polyclonal reactivity and size exceeding a threshold will 
engage low-affinity FcγR. While larger aggregates and insoluble ICs 
are cleared by the mononuclear phagocytic system in the liver and 
spleen, moderate to smaller ICs persist in the systemic circulation 
for a longer period and engage low affinity FcγRIIa and FcγRIIIa 
triggering proinflammatory responses. Smaller soluble ICs formed 
near the zone of molar equivalence (Heidelburger curve) cause 
Type III hypersensitivity reactions that are manifested through 
three key mechanisms: (1) Deposition of ICs at anatomical sites 
with diffuse capillary network and filtering membranes leading 
to vascular thrombosis and localized inflammatory response, (2) 
Propensity of some ICs to opsonize and activate complement (dis-
cussed below), and (3) Ability of ICs to cross-link FcγR and com-
plement receptors (CRs) on a variety of immune cells. Neutrophils 
account for 50–70% of circulating leukocytes and are often the first 
cells to be recruited at the site of IC deposition. They express two 
low-affinity FcγRs, FcγRIIA and FcγRIIIB, that can bind with both 
CICs and deposited ICs causing release inflammatory mediators 
(13). Besides FcγR, these cells also have CRs allowing them to bind 
to opsonized ICs. Perivascular and extravascular ICs first bind to 
FcγR on resident mononuclear cells (mast cells and macrophages), 
resulting in costimulation and a hyperactive state of these cells (11). 
FcR clustering from IC ligation triggers release of inflammatory 
mediators, and chemotactic chemokines that cause endothelial 
activation and further recruitment of neutrophils ultimately lead-
ing to IC-mediated tissue injury. These events serve to recruit and 
activate lymphocytes, monocytes, and dendritic cells, cells that play 
a vital role in the host adaptive immune response, thus, providing 
a mechanistic explanation of the innate immune system’s ability in 
influencing the immune system’s antigen-specific response.
TABLe 1 | Factors to be considered during immunogenicity risk assessment of a biotherapeutic.
Characteristics intrinsic to Risk 
potential
Considerations
Biotherapeutic structure and function
Structural and amino acid differences from native High Non-human sequences, low degree of humanization, and divergence of CDR sequences from germ 
line can break tolerance
Low Fully humanized sequences
Foreign protein to host High Enzyme replacement therapy to subjects with loss of function mutations in the proteins
Location of therapeutic target High Cell surface targets on immune cells that promote internalization, processing, and antigen presentation
Functional relationship with endogenous 
counterpart
High No redundancy in endogenous protein function; high neutralization potential
High Endogenous protein is in low abundance, e.g., recombinant protein therapy, likely to be neutralized at 
high doses
Low Endogenous protein is abundant; e.g., monoclonal antibody based therapeutics
Mode of action High Immunomodulatory; check point inhibitors
Low Immunosuppressive treatments
Predictive analytical data Varies In silico analysis of amino acid sequences with high binding to class II MHC allelic variants
Varies In vitro T cell stimulation assays using PBMCs from healthy donors
Biotherapeutic process and manufacturing
Chemical modifications Varies Oxidation, deamidation, isomerization have varying effects
Aggregation, denaturation High Repeat motifs cross-link B cell Ig receptors; unique conformational epitopes present in incorrectly 
folded denatured protein
Protein degradation High Structural variants can have unique linear and non-linear epitopes perceived as foreign
Contaminants and impurities High Host cell proteins, production, and purification process contaminants act as adjuvants
Post translational modifications Moderate α1-3 Gal, N glycolyl neuraminic acid, non-fucosylation are immunogenic risk factors
Formulation Varies Leachables in container, incompatibility with physiological pH, leading to product aggregation
Clinical use
Route of administration Varies Risk highest: Inhalation > subcutaneous > intraperitoneal > intramuscular > intravenous
Dose Varies Higher doses more likely to increase risk
Frequency of administration and duration of 
treatment
Varies Repeat dosage and prolonged exposure may either break or lead to tolerance
Patient
Age and genetic predisposition Varies Pediatric vs. adult immune system, HLA allelic subtypes, genetic defects, polygenic traits underlying 
immune system competence
FcγR polymorphism, FcγRIIIa expression on 
CD4+ T cells
Varies Expression levels, ratio, and cell type distribution of activating and inhibiting receptors
Preexisting antibodies and CD4+ T cells reactive 
to therapeutic
High Cross-reacting auto antibodies, preexisting anti-PEG antibodies
Disease status and chronicity Varies Autoimmune or proinflammatory predisposition has a higher risk; chronic ailments necessitate 
prolonged exposure
Prior exposure to related or cross- reacting 
therapeutics
High Common scaffold sequences or 2 unrelated therapeutics sharing the same altered Fc sequences or 
same linker
Concomitant medication Varies Co meds with immunosuppressive, such as methotrexate and steroids can reduce risk
Life threatening disease Low Higher tolerance to immunogenicity risk especially if no alternative therapy available
Other associated data
Other therapeutic programs with similar 
indication or similar therapeutic platforms
Varies Clinical data from other programs should be used as a guide for risk assessment
Non-clinical data Varies Non-clinical immunogenicity data are NOT predictive but useful for risk assessment if there is altered 
pharmacokinetic and efficacy data and immune adverse effects
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Immune complexes can lead to further ADA production and 
potential IC formation. The cross-linked Fc portions of IgG mole-
cules on an IC can: (a) bring together the FcR closer setting the stage 
for FcR activation, especially via ITAM bearing FcγRIIa and FcγRIIIa 
receptors. Monocytes, macrophages, and polymorphonuclear cells 
that express activating FcR produce proinflammatory cytokines in 
particular interferon (IFN)-γ that induces the expression of Class 
II MHC that further enhances the antigen uptake, processing, and 
presentation – eventually exacerbating a weak ADA response. (b) 
ICs carrying multiple therapeutic proteins can cross-link cognate 
B cell receptor (BCR) on the B cells producing the ADA, causing 
co-clustering of the BCR Ig alpha and beta chains leading to further 
activation of the B cells and more ADA (Figure 1).
Activation of Complement Cascade
In addition to FcγR, complement also plays a critical role in medi-
ating inflammatory processes downstream to formation of IC. ICs 
activate the complement cascade through the classical pathway by 
binding to complement component C1q via the Fc portion on ICs 
and unleashing a series of enzymatic activations and proteolytic 
events. The Fc of IgM ADA bearing ICs is very efficient in this 
reaction compared to IgG Fc. IgG3 ICs have greater propensity to 
fix complement than other IgG subclasses. Close proximity of IgG 
Fc on a complex mimics what IgM typically do best which is to 
efficiently activate complement system. Bringing the C1 complex 
close to one another lets them loose their inhibitor proteins and trig-
gers the classical pathway to generate C3 convertase. Complement 
Biotherapeuc
Complement opsonizaon, C1q, C3b, C3d, C4b, C4d, C5b-9
Leucocyte effector funcons mediated by cross-linking Fc and Complement receptors present on
• Neutrophils:  release chemoaractants, phagocytosis, localized inflammaon, IC vascular deposits
• Mast cells, basophils:  release chemoaractants, vasoacve products
• Monocytes and Macrophages:  release proinflammatory cytokines, e.g. interferon γ
• Dendric cells:  aain DC maturaon phenotype, enhance therapeuc uptake, increase in Class II MHC expression, 
Inducon of cosmulatory molecules expression, angen processing and enhanced angen presentaon to naïve 
CD4+ T cells and presentaon of therapeuc proteins by follicular dendric cells in germinal center to B cells
• B cells:  acvaon via crosslinked FcR and enhanced angen binding to BCR on marginal zone B cells, increase in Class 
II MHC expression and pepde presentaon
• T cells: FcγRIIIa mediated acvaon and interferon γ producon
IgM or IgG An 
drug anbody
Formaon of ADA + biotherapeuc soluble 
Immune complexes
Small complexes Medium size complexes
n
Therapeuc derived pepde loaded 
Class II MHC driven CD4+ T cell 
acvaon and expansion
B cell maturaon to plasma cells, 
producon of ADA
FiGURe 1 | The central role of immune complexes formed by biotherapeutic and ADA in the interplay between innate and adaptive arms of the 
immune system and exacerbation of ADA response. ADA specific to CDR of a monoclonal antibody therapeutic is used as an example for ease of representing 
complex formation of varying sizes where n represents the number of cross-linked ADA Fc in IC; in reality ADAs are polyclonal with varying specificities.
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opsonized IC in circulation is a danger signal. A key primary event 
is the generation of complement C3 that is cleaved by C3 convertase 
giving rise to C3a and C3b. C3b binding to C3 convertase leads 
to generation of C5 convertase that cleaves C5 to C5a and C5b. 
Ultimately this leads to generation of an inflammatory response 
through the formation of anaphylotoxins, such as C4a, C3a, and 
C5a (14). Engagement of C5a to its receptor CD88 or the formation 
of sub-lytic C5b-9 complexes on lymphocytes can trigger GPCR 
signaling responses that are typically seen with activation pathways. 
C5a receptor engagement on mast cells and macrophages plays a 
critical role in modulating the ratio of activating and inhibiting 
FcγR on those cells. CRs on neutrophils promote their recruitment 
to sites of IC deposits and subsequent inflammatory damage in 
the tissue. Neutrophils by virtue of their FcR and CR play a critical 
role in initiating and sustaining IC-mediated immune responses 
(13). Several other cell types express CRs – but of note are B cells 
and antigen-presenting cells (APCs) where CRs interacting with 
opsonized ICs lead to their activation, increased antigen process-
ing and presentation, and enhanced production of antibodies; this 
might be of significance allowing preexisting drug/ADA ICs to 
lead to higher ADA titers (Figure 1). ICs and complement can also 
directly influence T cell activation (15).
immune Complexes with Natural 
Antibodies
Preexisting antibodies that are predominantly IgM with low affin-
ity and broad specificity are secreted by CD5+ B1-b cells (16). 
Such antibodies have been described against hinge regions and 
known to form complexes. IgM bearing IC tend to be bigger in 
size and more likely to be trapped in lymphoid organs where they 
may promote T–B cell interaction. These antibodies are typically 
produced without external antigenic stimuli and have evolved to 
enhance the immunogenicity against pathogens. There are genetic 
differences in humans with respect to their amount and specificity 
and some of these show up as preexisting reactivity to therapeutic 
molecules in immunogenicity assays. Diversity and specificity of 
adaptive immune responses to a therapeutic may be influenced by 
these antibodies. Any immunogenic protein entering the systemic 
circulation can bind either to preexisting natural antibodies, cross-
reacting antibodies or to high-affinity class-switched antibodies 
elicited in response to the antigenic stimulus to form ICs.
Promoting B Cell Maturation
Initial priming of naïve B cells results from the recognition of 
BCR to an antigenic epitope on the therapeutic molecule that is 
either conformational or linear. Biotherapeutic bearing ICs can 
also be taken up by peripheral dendritic cells that then migrate 
to the spleen and present antigens to the B cells in the splenic 
marginal zone. ADAs generated through these processes bypass 
T cell help and are typically of IgM isotype or low-affinity IgG. 
They can form ICs with the therapeutic molecule and FcR- and 
CR-mediated pathways can promote their uptake and processing 
by antigen-processing cells, including splenic marginal zone B 
cells. Presentation of Class II MHC bound therapeutic-derived 
peptides by these cells can eventually activate CD4+ T helper 
cells if their T cell receptors recognize them as foreign epitopes. 
Some of the antigen-primed B cells migrate to germinal centers 
of lymph nodes and can make contact with follicular T helper 
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cells (TFH). Although epitopes from the therapeutic molecule 
that are recognized by T and B cells are fundamentally different, 
activated T cells secrete B cell growth factors that mediate T 
cell help and triggers formation of plasma cells from B cells, 
class switching, somatic hypermutation, production of high 
affinity ADA, and subsequent formation of memory B cells 
(17). Epitope spreading can also occur whereby novel epitopes 
formed within ICs with ADAs generated during a primary 
immune response are recognized by naïve B cells leading to 
their activation (10). FcR- and CR-mediated uptake of these 
ICs also induce antigen processing, and presentation leading to 
T cell activation and T cell-dependent ADA production by the 
B cells directed against an epitope different from the primary 
response. Follicular helper T cells are a specialized helper T cell 
population with a characteristic cell surface immunophenotype 
and their formation can be accentuated by the presence of IC. 
By virtue of homing to lymphoid organs, ICs can promote 
increased localized antigen concentration and presentation to 
the lymphoid cells.
effect on Follicular Dendritic Cells
Biotherapeutic drug bound ADA ICs above a certain size can 
bind through FcRs to follicular dendritic cells (FDC) present 
in the germinal center of lymph nodes. Furthermore, if com-
plement opsonized, these ICs will be efficiently captured by 
germinal center FDCs via CR-1 and CR-2. Both pathways clearly 
enhance the loading, processing, and presentation of any immu-
nogenic epitopes from the therapeutic protein and increase the 
opportunity of FDC recruiting TFH. This in turn will drive T 
cell–B cell interactions, a process necessary for B cell matura-
tion to plasma cells. Presence of biotherapeutic molecules in 
the complex that are bound to either FcR or CRs on FDC in 
the germinal center will contribute to B cell engagement with 
the biotherapeutic, and their selection of BCRs with respect to 
specificity and affinity (6, 10). Thus, complement opsonization 
is a critical event on IC since it results in enhanced targeting and 
cell surface localization of the therapeutic antigen to FDC, and 
subsequent increased and efficient antigen presentation to B cell. 
This process is essential for B cells to produce a sustained and 
high titer anti-drug antibody response.
Triggering Cytokine Signaling Pathways
Engagement of FcR or CR on cells though IC cross-linking 
results in the production of chemokines and growth factors that 
have a cascade effect on trafficking and growth of T and B cells. 
These soluble factors play a vital role, influencing the cross-talk 
between the innate and adaptive arms of immunity (18). Release 
of inflammatory cytokines that are routinely measured in various 
autoimmune disorders can also be indicative of drug-induced 
IC-mediated effects.
Direct influence of iC on T Cells
A subset of activated TFH express FcγRIIIa that can deliver a 
Class II MHC-independent activation signal and induce them to 
produce IFN-γ. Recognition of ICs by FcγRIIIa results in T cell 
costimulation and may represent an alternate pathway linking the 
innate and adaptive arms of immunity (19).
CLiNiCAL OUTCOMeS ReLATeD TO 
iMMUNe COMPLeXeS
Adverse effects to biological therapeutics arise either due to an 
exaggerated pharmacological activity toward its intended target 
or due to immune-mediated toxicity resulting from a necessarily 
long-term therapy (20). Immune response to the drug resulting 
in ADA generation and its associated downstream effects covers 
part of the overall spectrum of immune-mediated toxicity. The 
pathological mechanisms underlying immunotoxicity are diverse 
and have been reviewed by others (21). The examples covered 
in this article will focus on two scenarios on how IC formed by 
the ADA with the drug translates to a poor clinical outcome; 
one where binding by neutralizing ADA results in abrogation of 
pharmacological activity of the drug and second where the ADA 
causes sequestration of the therapeutic by formation of an IC 
with the drug, and causing enhanced clearance resulting from 
recognition of ICs by FcR. Together, these mechanisms result in 
loss of efficacy, altered pharmacokinetic profile, cross-reactivity 
to endogenous versions of the protein, and hypersensitivity reac-
tion manifested as infusion reactions to anaphylactic reactions 
(22–25). In general, these examples cover ADA responses to 
enzyme replacement therapeutics where the therapeutic is seen as 
a foreign protein in a host expressing the mutant allele, or to some 
recombinant protein therapeutics that result in breakdown of tol-
erance to the endogenous counterparts, and to some of the anti-
TNF-α agents and few other monoclonal antibody therapeutics, 
such as natalizumab (anti alpha4 integrin), and cetuximab (anti 
EGFR). It is important to emphasize on the perspective that while 
most biologics do elicit some titer of ADA with varying duration, 
a majority of them do not have overt clinical side effects. This 
may relate to the fact that formation of an IC may not necessarily 
relate to poor clinical response if the ADA levels are transient or 
low affinity and if there are enough active therapeutic molecules 
at the site of action to achieve a pharmacological response (26). It 
is possible that disease states can have an influence on the forma-
tion of ADA and, therefore, formation of IC. An autoimmune 
predisposition may result in an exaggerated immune response 
although no rigorous studies have been conducted comparing 
immunogenicity data in patients with rheumatoid arthritis or 
inflammatory bowel disease to patients with no underlying 
proinflammatory state. However, results with a drug such as 
belimumab, an antibody used for the treatment of lupus, a proto-
typical antibody-mediated disease, do not reveal higher rates of 
immunogenicity vs. antibody therapeutics in other indications. 
Other considerations that could impact clinical immunogenicity 
outcomes include mechanisms of action of immunomodulatory 
therapeutics that include binding and uptake of the therapeutic 
molecule by APCs, and subsequent activation and maturation of 
APCs, events that would clearly predispose to immunogenicity.
There is a considerable body of literature on immunogenicity 
to anti-TNF-α biologics and their role in immunopharmacologi-
cal adverse effects; this has been reviewed elsewhere (1, 24, 25, 
27–32). ADA responses to adalimumab and infliximab have been 
linked to clinically manifest adverse effects; by contrast, ADA 
responses to other anti-TNF-α therapeutics, such as etanercept, 
golimumab, and certolizumab, have not conclusively showed a 
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link to reduced clinical response (1). A significant percent of 
patients with rheumatoid arthritis receiving adalimumab and 
infliximab go on to develop ADA within the first 6 months of 
therapy (25, 28, 29). Likewise development of ADA and its role in 
serious side effects have been described for recombinant biolog-
ics, such as IFNs (33–35) erythropoietin (36), thrombopoietin 
(37), and Factor IX (38). Many of the adverse effects are most 
likely mediated by formation of ICs with the drug.
FACTORS MODULATiNG iMPACT OF 
iMMUNe COMPLeXeS
Immune complexes themselves are heterogeneous and vary with 
ADA titer, isotype distribution, specificity, affinity to the drug, 
size of the circulating complexes, and antigen. These attributes 
influence how their formation translates to clinical consequences.
Specificity
In terms of specificity, an ADA may either recognize the functional 
portion of a drug leading to abrogation of its pharmacological 
activity and thereby become a neutralizing antibody (NAb) or 
bind to pharmacologically irrelevant portions of the drug. While 
NAbs by virtue of their specificity prevent therapeutic target rec-
ognition, both NAbs and other binding antibodies can influence 
therapeutic exposure by either hastening the clearance of the drug 
(clearing antibodies) or enhance its circulating half-life (sustaining 
antibodies) (39). These two classes of ADAs may vary in titer and 
duration and thereby influence the outcomes. Patients treated with 
IFN-β had earlier onset, higher titers, and longer persisting non-
neutralizing ADA than neutralizing ADA (35, 40). ADA responses 
to anti-TNF-α agents have varied with the specific agent; ADAs 
elicited in adalimumab- and infliximab-treated patients were 
predominantly NAbs (41), while those receiving etanercept have 
mostly been non-neutralizing ADAs (1). Recombinant erythropoi-
etin and thrombopoietin therapies have resulted in ADAs that both 
cross react and functionally neutralize the endogenous versions 
often leading to serious clinical adverse effects (36, 37). Changes 
to the biophysical characteristics of the therapeutic protein often 
leading to aggregation can potentially break tolerance and lead to 
ADA formation reacting to the endogenous proteins. Likewise 
recombinant IFN-β1a and IFN-β1b therapy-induced ADA that 
was cross-reactive with endogenous IFN-β (42). Functional 
characterization of patient-derived NAbs to adalimumab (30, 41) 
by single B cell cloning revealed some interesting observations; 
there was clonal diversity within the anti-idiotypic population of 
NAbs and most bound to the drug with high affinity. The proclivity 
to form NAbs might be related to two factors: (a) the degree of 
divergence from germ line CDR sequences induced by extensive 
somatic hypermutation during therapeutic antibody engineering 
and (b) the number of idiotopes located within the drug’s target 
recognition domain. Despite minimal divergence from germ 
line sequence, adalimumab elicited higher than expected titer of 
NAbs; this was postulated due to extensive regions in its CDRs 
that conferred TNF-α recognition, thus, making it more likely for 
ADAs with such specificity to interfere with target recognition.
Multidomain therapeutics pose new challenges in dissecting 
the specificity of a polyclonal ADA response. Targeted cytokines 
made of an active cytokine covalently linked to Fab and Fc and 
antibody drug conjugates made with active payloads linked to an 
IgG through linkers are being developed as treatment modalities 
for cancer. These complex molecules can potentially elicit ADA 
reactivity to a variety of epitopes on the therapeutic and epitope 
characterization of ADA requires careful reagent development (43).
Size
Restriction of immunogenic specificity to a small region has an 
important bearing on the behavior of IC. The tighter the restric-
tion, greater is the likelihood of forming dimeric complexes of 
drug and ADA or formation of small ICs since steric hindrance 
of one ADA bound to the drug will restrict further ADAs from 
binding. This was indeed the case with adalimumab-specific IC 
formed in three representative patients’ samples that were studied 
by sucrose gradient fractionation and shown to be small and 
mostly dimeric in nature (41). However a more recent study by 
the same group also showed the presence of larger multimeric 
ICs formed by ADAs derived from B cells isolated from patients 
who were ADA positive to adalimumab (30). The implications 
of IC size may have a bearing towards altered pharmacokinetics; 
smaller complexes can persist for longer durations since they do 
not meet the minimal threshold to engage low-affinity FcR and 
will probably recycle the drug back into circulation through the 
FcRn pathway and larger complexes can be cleared faster and 
efficiently by low-affinity FcR recognition that mediate uptake 
and breakdown of the complexes. Infliximab bound ADA ICs 
were studied in cynomolgus monkeys (44) and human subjects 
(45), and showed formation of small complexes probably dimeric 
in nature and larger complexes that were tetrameric and higher. 
Larger complexes clear from the circulation faster than the 
smaller complexes (44), while smaller complexes could persist in 
circulation for up to 2 weeks (41). A comparative analyses of ICs 
resulting from different anti-TNF-α treatments has shown forma-
tion of smaller complexes with etanercept and larger complexes 
with adalimumab and infliximab (46). While larger complexes 
are picked up earlier by macrophages and cleared faster, they are 
also less likely to be available to trigger inflammatory pathways. 
Instead complexes that are opsonized by complement are more 
likely to be pathologic since they tend to be soluble, stay longer in 
systemic circulation, and would also engage B cells through both 
CR-2 and BCR. Such ICs can engage B cells through FcR, BCR, 
and CR-2 receptors, and deliver a potent signal.
initiation and Potentiation of immune 
Response
Specific recognition of a drug by a B cell is an early and necessary 
event in immunogenicity and T cell recognition of therapeutic-
derived peptides is necessary for B cell activation and maturation 
to plasma cells capable of producing high titer antibodies. ADAs 
are made by B cells utilizing T cell-independent and -dependent 
pathways. In general, drugs that tend to aggregate or multimerize 
can cause presentation of repeating epitopes that can cross-link 
BCR and clustering leading to their activation without T cell help 
(47–49); aggregation may also distort conformation resulting 
in novel B cell epitopes (50). Composition of the formulation 
or contamination with leachables and extractables may lead to 
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aggregation and be a risk factor for immunogenicity (51, 52). ICs 
with drug molecules trapped within them may also be engulfed by 
dendritic cells and be presented to splenic marginal zone B cells 
triggering another pathway of T-independent pathway of ADA 
(53). ADAs generated by this pathway are typically low affinity 
and IgM. However, mechanisms that allow the drug to get inter-
nalized, processed, and presented by Class II MHC on APCs and 
the presence of T cell epitopes in the primary sequence of the drug 
will promote T-dependent activation of B cells (54–56). Marginal 
zone splenic B cells or dendritic cells localized within tissue-
specific compartments important for surveillance may capture 
and process aggregated therapeutic or ADA bound complexes 
of therapeutic leading to antigen presentation to T cells. These 
pathways illustrate how a seemingly low-affinity T-independent 
generated ADA from a primary immune response could lead to 
formation of a drug–ADA IC which in turn through uptake by 
Class II bearing B cells or APCs could activate T cells and thereby 
leading to further B cell activation, epitope spreading, clonal 
expansion, affinity maturation, and generation of higher affinity 
ADA (Figure 1) (10, 16). The ICs formed early may also involve 
preexisting circulating IgM or IgG antibodies that recognize the 
biotherapeutic. Examples of these include antibodies recogniz-
ing polyethylene glycol (PEG) a frequently used covalent adduct 
for some biologics (57, 58) and also N-glycolylneuraminic acid 
a non-human sialic acid that gets incorporated into therapeutic 
proteins made from non-human mammalian cells (59). While 
aggregated therapeutics can be internalized through macropi-
nocytosis or phagocytosis or receptor-mediated endocytosis into 
APCs such as immature dendritic cells present locally at the site of 
administration, IC bearing drug molecules can also be taken up 
through Fc gamma receptors; further potentiating drug process-
ing and presentation by class II MHC on those APCs (60). This 
might also explain the observation that subcutaneous route of 
administration causes more immunogenicity than other routes 
probably due to the localization and proximity of the therapeutic 
to APCs such as Langerhans cells present locally. The importance 
of IC in exaggerating an immune response is further underscored 
if the complexes get opsonized with complement. Complement 
can potentiate uptake of the ICs through CR-1 and CR-2 receptors 
(61) and also play a role in the maturation of immature dendritic 
cells and expression of costimulatory molecules that eventually 
are required for T cell activation (42, 62, 63).
In some instances, immunogenicity is driven by breakdown of 
self-tolerance than a response to foreign epitopes. Several factors 
lead to this breakdown, including repeated exposure to a biothera-
peutic necessitated by the chronicity of the illness. At a molecular 
level, the coupling of T cell epitopes with self-antigens and a potent 
mechanism to ferry this therapeutic into dendritic cells with a 
mature phenotype combine together to break tolerance (49, 52).
isotype and Subclass
T cell help results in class switching and higher affinity ADAs 
typically of the IgG isotype (64). Anti-TNF-α agents such as 
infliximab and adalimumab that are known to elicit higher titers 
of NAbs tend to be more IgG1 and IgG4. The skewing of an ADA 
response to include more IgG4 subclass production can be seen 
over a period of time covering persistent ADA titers and may 
be due to repeated exposures to an immunogenic therapeutic 
(65–67). IgG4 ADAs have also shown to have higher neutral-
izing capability than IgG1 ADA probably due to the prolonged 
nature of antigen stimulation and repeated rounds required for 
affinity maturation (64, 68). However, this may be dependent 
on the nature of the therapeutic agent and there are instances 
with recombinant interferon treatment where most of the neu-
tralizing ADAs were IgG1 and not IgG4 (42). By contrast, IgM 
ADAs are considered to be of lower affinity and transient; any 
IgM bound therapeutic ICs can have more potent consequences 
than IgG complexes due to its multivalency and propensity to 
cross-link FcRs and fix complement. IgM type ADAs have been 
demonstrated with interferon-α 2b therapy (69) and TNF-α 
therapy; infusion reactions in some patients receiving infliximab 
were associated with presence of both IgE and IgM ADA in the 
serum (70). IgG1 and IgG4 antibodies are typically seen to protein 
antigens, IgG2 subtypes are induced by glycosylated epitopes (65).
Complement Activation
ADA-therapeutic IC activate complement. Only IgG and IgM 
isotypes are known to activate complement; the pentameric 
structure allows low levels of IgM bearing complexes to efficiently 
and readily activate complement. IgG1 and IgG3 subclasses are 
more potent complement activators than IgG2 and IgG4 (71). 
Complement opsonization by ICs can further potentiate a weak 
ADA to a higher titer ADA response. Products of complement 
activation directly or indirectly modulate dendritic cells and the 
humoral and cellular arms of the adaptive immune response. 
APCs bearing CR-1 and CR-2 can internalize complement 
opsonized ICs resulting in processing and presentation of thera-
peutic protein derived peptides to T cells (14, 63). In addition, 
complement proteins modulate T cells leading to their activation 
and differentiation, which influence B cell antibody production 
and memory cell formation (14). A study on the treatment of 
19 patients with relapsing-remitting multiple sclerosis with 
recombinant interferon-β showed interaction of ADA with the 
therapeutic interferon-β forming ICs and subsequent comple-
ment activation (42). IgE independent hypersensitivity reactions 
are mediated by IC-mediated complement activation and the 
acute phase reactants released downstream to complement 
activation (72).
Hypersensitivity Reactions
Fundamental to any type of hypersensitivity reaction is the 
formation of an IC of an ADA with its cognate partner. Such 
phenomena have been studied in both pre-clinical and clinical 
models (1, 4, 5, 24, 38, 73). In type I hypersensitivity, IgE isotype 
ADAs are formed during an initial response and upon repeat 
exposure to the therapeutic agent IgE bound complexes bind 
and cross-link to Fcϵ receptors on basophils and mast cells 
leading to acute degranulation, release of histamine, and mani-
festation of anaphylactic reaction. IgE-mediated anaphylaxis was 
documented in some patients receiving infliximab (70). Such 
reactions can also be potentially fatal. Atypical anaphylaxis can 
also be triggered with IgG isotype ADA when such IgG bearing 
ICs formed after a second exposure cross-link Fcγ receptors on 
neutrophils leading to activation and release of platelet activating 
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factor supposedly more potent than histamine (74, 75). Type III 
hypersensitivity involves formation of large ADA/therapeutic 
protein complexes in the correct stoichiometry that do not get 
cleared but instead precipitate and deposit in tissues rich in 
filtering membranes made of fenestrated endothelium, such as 
kidneys, synovial membranes, and the choroid plexus. Animal 
necropsy studies have shown deposits are typically formed in 
post capillary venules. Further downstream tissue damage is 
mediated by complement fixation and activation or Fc-mediated 
inflammatory sequelae. This type of hypersensitivity is highly 
dependent on the ADA/drug ratio in the complex and might 
explain why it is relatively rare and variably seen despite the ease 
of forming CICs. The pathology is multifocal and accompanied 
by cell death and compromised organ function. Venous and arte-
rial thromboembolic phenomena with high titer ADA have been 
described in three patients receiving adalimumab treatment. The 
underlying pathology in these patients is related to IC formation 
with adalimumab ADA and its downstream effects. Presence of 
anti-adalimumab ADA in a cohort of patients in the same study 
was associated with higher risk of developing thromboembolism 
(76). Clinical manifestations and humoral and cellular immunity 
pathways associated with drug-induced hypersensitivity reac-
tions have been well reviewed elsewhere (73).
ANALYTiCAL CHALLeNGeS iN THe 
ASSeSSMeNT OF iMMUNe COMPLeXeS
Most assays used for screening for the presence of ADA utilize a 
bridging assay format that allows two labeled drug molecules to 
be bridged by an ADA; in some instances, the ADA is captured 
first by drug attached to the surface of a plate and then detected by 
a second antibody. The bridging format depends on the bivalency 
or multivalency of the ADA and may fail to detect IgG4 subclass 
ADA that typically starts to appear much later after prolonged 
exposure to drug. Formation of interchain disulfide bonds in the 
hinge region of IgG4 molecules is inefficient and could result in 
formation of either IgG4 halfmers or heterodimers; such ADA 
molecules presenting as monovalent binding molecules would 
be unable to form a bridge between two drug molecules (66). 
Cross-binding of labeled drug molecules in presence of rheuma-
toid factor, anti-allotypic antibodies, or soluble target and epitope 
masking on labeled drug molecules as in a solid-phase capture 
reagent are some reasons for false-positive and false-negative 
data (77). Comparative analysis of ADA responses to different 
therapeutic agents to a common target are influenced not only 
by intrinsic differences between the therapeutic agents, and lack 
of consistency in study design, influence of immunosuppres-
sive comedications, sampling time, and methodologies but also 
profoundly influenced by the semi-quantitative nature of the 
immunogenicity assay, differences in the assay formats used to 
measure the ADA and most importantly the assay’s tolerance to 
levels of circulating therapeutic (78–80). Several techniques, such 
as acid dissociation, are used to overcome the drug interference 
in ADA detection and many of these methods are laborious 
and might alter properties of ADA that affect their detection in 
assays (79, 80). This affects interpretation of ADA levels against 
any given therapeutic determined at different time points in the 
same study population or in different disease states or in subjects 
with different routes of administration of the therapeutic. More 
importantly, choice of reagents, controls, and assay design will 
limit any conclusions that can be made from studies attempting 
to compare immunogenic profiles of different therapeutic agents 
or modalities of treatment.
Attempts to measure both bound ADA within ICs and free 
ADA as a representation of total ADA levels have been limited. A 
versatile and elegant generic method of measuring bound as well 
as total ADA in cynomolgus serum samples dosed with human 
Fc-based therapeutics was described by Stubenrauch et al. (81). 
They were able to differentiate total from bound ADA by compar-
ing samples spiked with drug in vitro to samples that were not. 
The method depends on the availability of well-characterized 
reagents with specific reactivity to human IgG or cyno IgG but 
not cross-reacting to both. The method demonstrated value in 
picking up ADA responses earlier in the study and also detecting 
ADA even at drug levels that inhibited their detection in the tra-
ditional bridging assay format. Such methods may not be feasible 
with clinical samples where cross-reactivity with normal human 
IgG would adversely affect the assay. Methods developed by our 
group took advantage of a non-Fc bearing therapeutic protein 
to detect drug–ADA ICs in cynomolgus samples and arrived at 
similar conclusions that ADA bound in ICs significantly limited 
their detection by bridging assay format (82). A key consideration 
for any assay designed to detect drug-specific ICs would be the 
choice between using covalently or non-covalently coupled drug 
and ADA complexes for method development and calibration. 
While covalent coupling in the ratio of 1 ADA to 1 drug molecule 
provides consistency across assays, it does not fully represent 
the diverse range of ICs seen in actual samples and, therefore, 
may not provide an accurate estimation (82). In another study, 
formation of infliximab and anti-infliximab IC in human sub-
jects was tracked and characterized by infusing radiolabeled 
infliximab to four patients, two of whom were non-responders. 
Whole-body imaging and sucrose gradient separation of serum 
samples revealed formation of higher ADA levels and large ICs 
in non-responders with faster clearance of infliximab and uptake 
of radiolabeled drug in liver and spleen (45). As discussed earlier, 
larger ICs are generally cleared faster through FcR recognition 
and internalization by cells of the reticulophagocytic system.
Several groups have used some unique attribute of ICs in 
general to estimate total ICs; these include complement binding 
and there are commercial kits (Quidel MicroVue, CIC-RAJI 
EIA, Cat #A002) that make use of this property (83). CICs 
bind on red blood cells through CR-1, which is a mechanism 
for their removal. It is a marker that can be measured by flow 
cytometry and varying expression may be associated with clear-
ance of the complex; lower expression may be associated with 
reduced clearance and increased risk of IC-mediated adverse 
effects. Other assays have been described measuring circulating 
and opsonized complement (84). Commercial kits that measure 
C3a and C5b-9 (Quidel MicroVue SC5b-9 Plus EIA) can be 
used as indicative of complement activation. These have been 
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reviewed by others (5). Higher levels of C3a and C5b-9 are 
indicative of complement activation. These assays are not rou-
tinely performed and lack standardization in procedures across 
laboratories. International standards for complement assays 
have been published and need to be uniformly adopted (84). 
Measurement of complement products directly bound to the 
drug-specific IC is physiologically more relevant and eliminates 
interference due to variations in protein metabolism, or other 
autoantibodies. Such technologies are being evaluated here and 
elsewhere wherein specific immunocapture of total drug from 
biological samples followed by mass spectrometric analysis of 
signature peptides specific to complement components on the 
C1q and C5b-9 that might have covalently reacted with the 
IC would reveal the extent of opsonization. Using the same 
approach, one could even isotype the distribution of IgM and 
IgG subtypes in the IC. These methods are distinct from some 
of the currently available isotyping platforms that only study free 
ADA in the sample.
It should be emphasized that assays that identify CICs or prod-
ucts of complement activation do not provide specific informa-
tion on therapeutic bound to ADA ICs and CICs in general can 
be elevated following infection, or patient’s disease state such as 
autoimmune condition. Identification of drug-specific ICs would 
need reagents with exquisitely defined specificities. Using samples 
from animal studies might be a better approach than human study 
samples to study ICs with therapeutic humanized antibodies. ICs 
may also be present in serum of normal healthy adults and not 
all drug–ADA complexes are necessarily pathological; those that 
are significant would be dependent on (a) their size and binding 
to low-affinity FcγR on phagocytic cells causing faster clearance 
of the therapeutic and (b) their ability to opsonize and activate 
complement leading to inflammatory sequelae. These outcomes 
are clinically relevant. Our work on ICs in cynomolgus monkeys 
showed that only a fraction of total drug-specific ICs were bound 
to the low-affinity FcγR and despite high levels of drug-specific 
ICs in circulation, there was no evidence of complement-medi-
ated activation or inflammatory cytokine elevation (82) in the 
monkeys. With this in perspective, it would be more meaningful 
to assess size, clonality, IgG subtype, or IgM composition of the 
complex and any evidence of ongoing opsonization – all factors 
that could influence FcγR binding or complement activation. 
Demonstrating just the presence of a drug and ADA complex may 
not be any more helpful from a clinical standpoint than showing 
presence of ADA in the serum.
The use of immunohistochemistry techniques using specific 
reagents to follow drug-induced ICs along with colocalization 
of terminal complement present around cynomolgus monkey 
tissues from toxicology studies have also been described (5). 
Likewise morphological data to support drug-induced hypersen-
sitivity reaction and IC deposition around sub-endothelial and 
sub-epithelial regions of the glomeruli can be enhanced through 
the use electron microscopy (5). It is critical that any technique 
studying the distribution of ICs or activated complement prod-
ucts in any biological material must demonstrate the presence 
of the therapeutic molecule with specific reagents to support 
pathology, resulting from drug-induced ICs. Such interpretations 
should not be confounded by reagent cross-reactivity to endog-
enous IgG. Reagents that bind to human IgG that is a commonly 
used therapeutic platform must be cross adsorbed to ensure no 
binding with monkey or the relevant species’ IgG. In order to 
broaden our understanding of phenomena linked to formation 
of ADAs, comparative data across different therapeutic platforms 
and disease backgrounds will be important and will, therefore, 
require some minimum consistency in controls and procedures.
TOwARD A ROAD MAP FOR IN VIVO RiSK 
ASSeSSMeNT FOR iMMUNOGeNiCiTY
There are several factors that make individuals in a population 
respond distinctly to a therapeutic and also play a possible role in 
the immune pathways. Allelic polymorphism in MHC plays a key 
role in T cell activation and plasma B cell proliferation and dif-
ferentiation leading to production of ADA (17). But these studies 
have been limited only to a few commonly expressed alleles and 
focus solely on the cellular immunity pathways. The ability of 
drug-specific ICs to fix complement, trigger ADCP or ADCC 
can influence long-term outcomes. These variables are related 
as discussed earlier to the clonality of ADA and thereby the size 
of the complex, the isotype  –  with IgM and IgG3 being most 
efficient in fixing complement and also the microenvironment 
of drug interaction with the target. Tissue microenvironment 
can comprise stromal inflammation, localized concentration of 
cytokines, acute phase reactants, and presence of proteases and 
granzymes secreted from T cells and neutrophils that can lead 
to protein degradation and epitope generation. FcR polymor-
phisms within individuals in a population specifically related to 
the mutations that affect IC binding would significantly affect 
IC clearance and function of various immune cells (12). In this 
regard, it would be interesting to develop and use flow cytometry 
techniques to specifically immunophenotype-activated T and B 
cells in samples that test positive for ADA and identify FcγRIIb 
variants and their distribution on B cells and FcγRIIIa on T cells. 
These markers need to be compared to their baseline expression 
and correlated with other early and late activation markers of 
immune cell activation. Members of the Siglec family of cell sur-
face proteins, also called CD33, show variation between individu-
als and are known to regulate immune activation of T and B cells 
(85). Preexisting antibodies or CD4+ T cells reactive to specific 
epitopes on the drug molecule could play a role through forma-
tion of ICs with the drug that can boost the immune response or 
cause epitope spreading as discussed earlier. Preexisting antibod-
ies to N-glycolylneuraminic acid (59) and PEG (58) have been 
implicated in higher immunogenicity to biotherapeutics. Any 
comparative assessments of immunogenicity profiles of differ-
ent classes of therapeutics should be considered not only in the 
context of underlying disease state as mentioned earlier, but also 
whether patients were treated with immune modulating come-
dications. Anti-TNF-α drugs are used in rheumatoid arthritis 
and Crohn’s disease/Ulcerative colitis patients. Approximately, 
80% of patients in all disease indications use anti-TNF-α drugs in 
combination with an immunosuppressive such as methotrexate. 
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Hence, it is likely there will not be a difference in immunogenic-
ity across these different diseases.
Clearly, for any in vivo evaluation to be of value for immuno-
genicity risk assessment, there must be a few criteria. First, the 
biological characteristic under question must be responsive to 
perturbation of the immune system, when compared to a pre-
defined baseline profile and preferably must have a mechanistic 
connection with clinical adverse effects. As emphasized earlier, 
there has to be underlying variations in their levels of expression 
or in the expression of alternate allelic forms or variants between 
individuals in a population that might modulate the immune 
response to the therapeutic. Their sampling must be easy and 
made accessible for exploratory work, reagents must be readily 
available and well characterized and most importantly the assays 
should be well standardized across multiple studies, diseases, 
sites, and therapeutic platforms for meaningful comparative 
research. Lastly, the data have to be amenable for multivariate 
analysis to make any correlations with ADA titers, its kinetics, 
and population frequency and with clinical outcomes to be of any 
predictive value. Hopefully systems pharmacology approaches 
can provide modeling of subtle person-to-person, and disease-
to-disease variations that make it more or less likely for an ADA 
response to form, and demonstrate how this information can 
be integrated within the context of ADA risk assessment. Such 
an endeavor might benefit from an open source medium of 
exchange of materials and data through a consortium. Significant 
attempts have been made drawing together collaborators across 
the biotechnology industry, academia, and regulatory agencies in 
the ABIRISK consortium to standardize and define end points, 
materials and methods, and share the learnings (86).
CONCLUSiON
Most recombinant engineered therapeutic proteins are adminis-
tered to patients as repeated doses, over their lifetime. Generation 
of ADA is a potential outcome to almost all such therapeutics. 
These can form ICs with the therapeutic which in turn can drive 
more ADA formation. Clinical consequences of ADA make 
a compelling case for early IC formation that is an important 
consideration whether or not a long-lasting, pharmacologi-
cally meaningful ADA response will form. With the advent of 
personalized treatment, there will be a greater need to monitor 
underlying differences between individuals who are reactive 
to a therapeutic and how they impact either their response to 
treatment or their manifestation of any immunological adverse 
effects. Clinical decisions in routine practice rarely make use of 
information on the patient’s immune response to a therapeutic as 
a basis to understand poor therapeutic response or an unexpected 
adverse effect; to some extent, this has been due to limitations to 
identify the right dose of the drug required to neutralize the target 
in the presence of ADA, challenges in ascertaining total amount 
of ADA, and a general lack of immunogenicity assessments in 
patients to investigate failure of response after a drug has been 
approved for market. The semi-quantitative nature of routine ADA 
assays, and diversity in assay formats and platforms also make it 
difficult to make meaningful comparisons in immunogenicity 
data across multiple therapeutics that a clinician might consider 
for treatment of a specific disease. Instead, the approach has been 
to switch to an alternate treatment (77) or take advantage of other 
immunomodulatory agents that negate the titer and impact of 
ADA. Patients with autoimmune conditions, such as rheumatoid 
arthritis, spondyloarthritis, and Crohn’s disease, and treated with 
anti-TNF-α agents have benefited from concomitant methotrex-
ate treatment (87). Clinicians should be aware that formation of 
ICs and the accompanying risks they entail could persist as long 
as the same treatment continues unabated even with sympto-
matic remediation of adverse effects. Despite understanding and 
mitigating risk from the therapeutic aspect, such as selecting the 
right molecular structure and sequence, formulation, preventing 
aggregation, and choosing appropriate routes of dosing, the ques-
tion on why some individuals and other do not develop clinically 
significant ADA titers persists and has also been discussed (3). 
Some aspects, such as genetic differences, HLA allelic variants, 
underlying disease state, and presence of preexisting reactive T 
cells and natural antibodies, might shed additional clarity on this 
variability. However, the formation and contribution of ICs is 
central to most of the downstream sequelae that are seen follow-
ing development of ADA. Of particular importance, is the role 
of IC with low affinity non-neutralizing binding ADA; these IC 
through FcR interaction, complement fixation and subsequent 
downstream effects on APCs and B cells, further potentiate the 
ADA response leading to epitope spreading of ADA, formation 
of neutralizing antibody, ADA affinity maturation and further IC 
formation. The study of IC biology specific to the therapeutic will 
shed more light on the role and relationship of ADA to clinical 
outcome measures.
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